Chronic Urticaria Treatment Challenges in Children
Author Information
Author(s): Ensina Luis Felipe, Brandão Larissa Silva, Melo Ana Caroline Dela Bianca, Antila Martti, Ben-Shoshan Moshe, Solé Dirceu
Primary Institution: Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Hypothesis
This paper aims to review the efficacy and safety of current chronic urticaria (CU) treatment in children and the existing patient-reported outcome measures (PROMs) used in this age group.
Conclusion
The existing data indicate that these drugs are safe and effective for treatment when dose adjustments are made.
Supporting Evidence
- The effectiveness of high doses of antihistamines in children has been demonstrated with control rates ranging from 35% to 92%.
- Omalizumab is approved for children over 12 years of age as a second step in the treatment algorithm.
- Some data show complete control of symptoms in more than 80% of pediatric cases with no adverse effects.
- When monitored closely, cyclosporine showed a good response rate in pediatric CU with few adverse events.
- PROMs validated for this age can be helpful in clinical decisions.
Takeaway
This study looks at how to treat a skin problem called chronic urticaria in kids, showing that some medicines can help a lot when given in the right amounts.
Methodology
The authors performed a non-systematic review of published articles in English, Spanish, and Portuguese in the PubMed database in the last decade.
Potential Biases
Potential conflicts of interest were noted for some authors due to funding and consultancy roles.
Limitations
The study highlights the need for more collaborative studies to generate stronger evidence.
Participant Demographics
Children with chronic urticaria, with a median age of 9.5 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website